Pretreatment samples obtained from melanoma patients who later responded to pembrolizumab therapy showed a higher number of CD8-positive, PD-1-positive, and PD-L1-expressing cells at the invasive tumor margin and inside tumors (52). This evidence concerns the gene CD8A and melanoma.